ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
View original at finance.yahoo.comZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations Only approved oral, single agent, targeted therapy for these patients following platinum-based chemotherapy Launch expands AstraZeneca's commitment to addressing substa…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Real-world evidence shows a five-year overall survival rate as low as 8% for patients with EGFR exon 20 insertion mutations, who have historically had limited targeted treatment options and poor outcomes.
60% confidenceSunvozertinib offers an oral, once-daily targeted treatment option recommended in clinical practice guidelines for patients with EGFR exon 20 insertion-mutated lung cancer who have progressed after platinum-based chemotherapy.
60% confidenceZEGFROVY is the only approved oral, single-agent, targeted therapy for patients with previously treated EGFR exon 20 insertion-mutated NSCLC following platinum-based chemotherapy.
60% confidenceThe US launch of ZEGFROVY marks an important step in AstraZeneca's commitment to the EGFR-mutated lung cancer community, bringing an oral, mutation-specific option to a distinct patient population with substantial unmet need.
60% confidenceThe ZEGFROVY launch expands AstraZeneca's commitment to addressing substantial unmet need across EGFR-mutated lung cancer with a proven portfolio of medicines targeting EGFR mutations.
60% confidenceIn the WU-KONG1B trial, ZEGFROVY showed a confirmed overall response rate of 46% (n=85; 95% CI 35, 57) and a median duration of response of 11.1 months among responders (n=39; 95% CI 8.2, NE); 72% of responders had duration of response of at least six months.
60% confidence